| Autor: |
Kohei, Fujita, Nobuhiro, Haruki, Hiroki, Kurehara, Nobuo, Ochi, Yushi, Yamakawa, Shinnosuke, Harata, Chisa, Tsumoto, Takuma, Tsuji, Tsuyoshi, Ito, Ayaka, Izumi, Rena, Usui, Noriyuki, Shinoda |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Gan to kagaku ryoho. Cancerchemotherapy. 47(6) |
| ISSN: |
0385-0684 |
| Popis: |
Immune checkpoint inhibitors(nivolumab)have been recommended as third-line chemotherapy for advanced gastric cancer(AGC)according to the Guidelines of Gastric Cancer(5th edition). Therefore, they have been used in daily clinical practice. On the other hand, the neutrophil-lymphocyte ratio(NLR)has been reported to be associated with the prognosis of cancer patients.Twenty patients treated with nivolumab for AGC between January 2018 and November 2019 were retrospectively examined.Median age of the 20 patients(18 males, 2 females)was 70 years(55- 84 years). Nivolumab was administered as second-, third-, fourth-, and fifth-line therapy in 1, 11, 7, and 1 case, respectively. The best tumor response evaluation was observed in PR 1, SD 7 and PD 10 cases. Median overall survival(OS)was 10 months, and median progression-free survival(PFS)was 3 months. No serious adverse events occurred. Compared to the NLR2.0 group, OS significantly prolonged(2.2 months vs 21.9 months)and PFS tended to prolong(1.4 months vs 6.2 months)in the NLR≤2.0 group.NLR may be an effective prognostic factor in patients with AGC receiving nivolumab treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
